Literature DB >> 22660025

Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism.

M D Walker1, T Rundek, S Homma, M DiTullio, S Iwata, J A Lee, J Choi, R Liu, C Zhang, D J McMahon, R L Sacco, S J Silverberg.   

Abstract

OBJECTIVE: We recently demonstrated that mild primary hyperparathyroidism (PHPT) is associated with increased carotid intima-media thickness (IMT) and stiffness, and increased aortic valve calcification. It is unclear whether parathyroidectomy (PTX) improves these abnormalities. The purpose of this study was to determine whether cardiovascular abnormalities in PHPT improve with PTX.
DESIGN: Forty-four patients with PHPT were studied using carotid ultrasound and transthoracic echocardiography before and after PTX. Carotid IMT, carotid plaque and stiffness, left ventricular mass index (LVMI), myocardial and valvular calcification, and diastolic function were measured before, 1- and 2-year post-PTX.
RESULTS: Two years after PTX, increased carotid stiffness tended to decline to the normal range (17%, P=0.056) while elevated carotid IMT did not improve. Carotid plaque number and thickness, LVMI and cardiac calcifications did not change after PTX, while some measures of diastolic function (isovolumic relaxation time (IVRT) and tissue Doppler peak early diastolic velocity) worsened within the normal range. Indices did improve in patients with cardiovascular abnormalities at baseline. Increased carotid stiffness improved by 28% (P=0.004), a decline likely to be of clinical significance. More limited improvements also occurred in elevated IMT (3%, P=0.017) and abnormal IVRT (13%, P<0.05), a measure of diastolic dysfunction.
CONCLUSIONS: In mild PHPT, PTX led to modest changes in some cardiovascular indices. Improvements were mainly evident in those with preexisting cardiovascular abnormalities, particularly elevated carotid stiffness. These findings are reassuring with regard to current international guidelines that do not include cardiovascular disease as a criterion for PTX.

Entities:  

Mesh:

Year:  2012        PMID: 22660025      PMCID: PMC3668344          DOI: 10.1530/EJE-12-0124

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  55 in total

1.  Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism.

Authors:  Anita Persson; Jens Bollerslev; Thord Rosen; Charlotte L Mollerup; Celina Franco; Gunhild A Isaksen; Thor Ueland; Svante Jansson; Kenneth Caidahl
Journal:  Clin Endocrinol (Oxf)       Date:  2011-02       Impact factor: 3.478

2.  Pulse pressure amplification a mechanical biomarker of cardiovascular risk.

Authors:  Athanase Benetos; Frédérique Thomas; Laure Joly; Jacques Blacher; Bruno Pannier; Carlos Labat; Paolo Salvi; Harold Smulyan; Michel E Safar
Journal:  J Am Coll Cardiol       Date:  2010-03-09       Impact factor: 24.094

3.  Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism.

Authors:  Giuseppe Schillaci; Giacomo Pucci; Matteo Pirro; Massimo Monacelli; Anna Maria Scarponi; Maria Rosaria Manfredelli; Fabio Rondelli; Nicola Avenia; Elmo Mannarino
Journal:  Atherosclerosis       Date:  2011-05-18       Impact factor: 5.162

4.  One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease.

Authors:  Graziano Riccioni; Nicola Vitulano; Barbara Mancini; Alessandra Zanasi; Nicolantonio D'Orazio
Journal:  Pharmacology       Date:  2010-01-21       Impact factor: 2.547

5.  Cardiac structure and diastolic function in mild primary hyperparathyroidism.

Authors:  M D Walker; J B Fleischer; M R Di Tullio; S Homma; T Rundek; E M Stein; C Zhang; T Taggart; D J McMahon; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

6.  Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.

Authors:  M L Bots; M K Palmer; S Dogan; Y Plantinga; J S Raichlen; G W Evans; D H O'Leary; D E Grobbee; J R Crouse
Journal:  J Intern Med       Date:  2009-03-02       Impact factor: 8.989

7.  Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy.

Authors:  P Farahnak; M Ring; K Caidahl; L-O Farnebo; M J Eriksson; I-L Nilsson
Journal:  Eur J Endocrinol       Date:  2010-06-18       Impact factor: 6.664

8.  Carotid vascular abnormalities in primary hyperparathyroidism.

Authors:  M D Walker; J Fleischer; T Rundek; D J McMahon; S Homma; R Sacco; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2009-09-15       Impact factor: 5.958

9.  Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population.

Authors:  Rasmus Mogelvang; Peter Sogaard; Sune A Pedersen; Niels T Olsen; Jacob L Marott; Peter Schnohr; Jens P Goetze; Jan S Jensen
Journal:  Circulation       Date:  2009-05-11       Impact factor: 29.690

10.  A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS).

Authors:  Ning Yu; Peter T Donnan; Graham P Leese
Journal:  Clin Endocrinol (Oxf)       Date:  2011-08       Impact factor: 3.478

View more
  19 in total

1.  The impact of obesity on the presentation of primary hyperparathyroidism.

Authors:  Hien Tran; Jacob S Grange; Beverley Adams-Huet; Fiemu E Nwariaku; Jennifer L Rabaglia; Stacey L Woodruff; Shelby A Holt; Naim M Maalouf
Journal:  J Clin Endocrinol Metab       Date:  2014-03-31       Impact factor: 5.958

2.  Emerging data on cardiovascular risk in primary hyperparathyroidism.

Authors:  Jessica Pepe; Sara Piemonte; Cristiana Cipriani; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

3.  The use of intraoperative parathyroid hormone monitoring in minimally invasive parathyroid surgery.

Authors:  J Helbrow; A E Owais; A G Sidwell; L M Frank; M E Lucarotti
Journal:  Ann R Coll Surg Engl       Date:  2016-07-14       Impact factor: 1.891

4.  Parathyroid hormone is related to QT interval independent of serum calcium in patients with coronary artery disease.

Authors:  Nicholas O Palmeri; Karina W Davidson; William Whang; Ian M Kronish; Donald Edmondson; Marcella D Walker
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-26       Impact factor: 1.468

Review 5.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

6.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

7.  The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  Maryam Yavari; Awat Feizi; Fahimeh Haghighatdoost; Azin Ghaffari; Hassan Rezvanian
Journal:  Endocrine       Date:  2020-10-15       Impact factor: 3.633

Review 8.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

Review 9.  Primary hyperparathyroidism and hypertension.

Authors:  Sarah B Fisher; Nancy D Perrier
Journal:  Gland Surg       Date:  2020-02

Review 10.  Effect of Parathyroidectomy Upon Left Ventricular Mass in Primary Hyperparathyroidism: A Meta-Analysis.

Authors:  Donald J McMahon; Angela Carrelli; Nick Palmeri; Chiyuan Zhang; Marco DiTullio; Shonni J Silverberg; Marcella D Walker
Journal:  J Clin Endocrinol Metab       Date:  2015-10-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.